Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Translational research

1930O - Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT)


19 Sep 2020


Proffered Paper - Translational research


Targeted Therapy;  Translational Research

Tumour Site


Patricia Martin Romano


Annals of Oncology (2020) 31 (suppl_4): S1034-S1051. 10.1016/annonc/annonc294


P. Martin Romano1, L. Mezquita2, L. Lacroix3, E. Rouleau4, A. Varga5, C. Baldini1, S. Postel-Vinay6, L. Friboulet7, A. Geraud6, M. Aldea8, A. Gazzah6, Y. Loriot9, J. Soria6, F. André10, A. Hollebecque6, B. Besse11, C. Massard12, A. Italiano1

Author affiliations

  • 1 Ditep, Gustave Roussy, 94805 - Villejuif/FR
  • 2 Medical Oncology, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 3 Translational Research Laboratory, Gustave Roussy - Cancer Campus, 94800 - Villejuif/FR
  • 4 Tumor Genetics, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 5 Ditep - Département D’innovation Thérapeutique Et D’essais Précoces, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 6 Ditep, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 7 U981, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 8 Medical Oncology Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 9 Cancer Medicine Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 10 Medical Oncology, Institut Gustave Roussy, Villejuif/FR
  • 11 Dept Of Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 12 Ditep, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1930O


Comprehensive genomic profiling (CGP) in advanced solid tumors has led to implement precision medicine in clinical practice. However, genomic alterations (GAs) detected are still not routinely used for therapeutic decision in the majority of the tumor types. The ESMO ESCAT ranks the GAs based on their clinical actionability. Since 2018, our Molecular Tumor Board (MTB) stratified the GAs detected in tissue/liquid biopsy based on ESCAT to guide treatment selection. Based on ESCAT, we aimed to assess clinical actionability of GAs through our MTB.


Patients (pts) with metastatic solid tumors enrolled in MOSCATO (NCT01566019) and MATCHR (NCT02517892) trials underwent a tumor biopsy at time of relapse. Molecular profiling was performed using next-generation sequencing (NGS), whole-exome sequencing and RNA-sequencing. Clinical actionability of GAs was prospectively assessed at our MTB according to ESCAT tiers. Clinical characteristics and outcome of pts were also collected.


Between Nov 2018 and March 2020, 387 pts underwent a biopsy. Molecular data from 366 pts were interpreted at the MTB. Median age was 61 (range, 24-90); 221 pts (60%) were male. Twenty-seven different tumor types were discussed; the most common were lung (n=117, 32%), gastrointestinal (n=105, 28%) and urological cancer (n=60; 16%). At least one GA was detected in 94% (366/388; 5% failed analysis). Based on ESCAT, GAs were classified according to the tumor type: 20% were tier I [N=72: 25 EGFR mutation (m), 6 ALK rearrangement (r); 6 FGFRr, 4 BRAFV600Em; 9 RETr, 9 RETm; 5 MSI-H; 3 ROS1r; 2 HER2a; 2 BRCAm; 1 METm]; 7% as tier II (n=25: 19 KRASG12Cm; 3 BRAFV600Em [other than lung/melanoma]; 2 METa; 2 HERm); 19% as tier III (n=48) and 16% as tier IV (n=59). Based on ESCAT, CGP reported clinically informative results in 117 pts (32%) and guiding treatment selection in 73 pts (20%). Clinical outcomes (progression free survival; response rate) by ESCAT tier will be presented during the meeting.


ESCAT classification of genomic alterations is attainable in clinical practice through MTB and helps adjusting treatment on both standard of care or investigational settings. Since ESCAT tiers update regularly, a dynamic review of therapeutic choices is advised.

Legal entity responsible for the study

Gustave Roussy.


Gustave Roussy.


P. Martin Romano: Research grant/Funding (institution): BMS; Research grant/Funding (institution): Astrazeneca. L. Mezquita: Advisory/Consultancy, Speaker Bureau/Expert testimony: Bristol-Myers Squibb. L. Lacroix: Research grant/Funding (institution): AstraZeneca. A. Varga: Research grant/Funding (self), Research grant/Funding (institution): AstraZeneca. C. Baldini: Advisory/Consultancy: Bristol-Myers Squibb. S. Postel-Vinay: Research grant/Funding (self), Research grant/Funding (institution): Boehringer Ingelheim; Travel/Accommodation/Expenses: AstraZeneca. L. Friboulet: Travel/Accommodation/Expenses: AstraZeneca. A. Gazzah: Research grant/Funding (institution), Non-remunerated activity/ies, Principal/sub-Investigator: AstraZeneca. J-C. Soria: Shareholder/Stockholder/Stock options: AstraZeneca. A. Hollebecque: Research grant/Funding (institution), Non-remunerated activity/ies: Bristol-Myers Squibb. B. Besse: Research grant/Funding (institution), Non-remunerated activity/ies: Boehringer Ingelheim. C. Massard: Research grant/Funding (institution), Non-remunerated activity/ies: Principal/sub-Investigator; Research grant/Funding (institution): Research Grants; Non-remunerated activity/ies: Non-financial support (drug supplied). A. Italiano: Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy: Epizyme; Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy: Philips; Advisory/Consultancy, Research grant/Funding (institution): MSD; Advisory/Consultancy: Springworks; Research grant/Funding (institution): BMS; Research grant/Funding (institution): Merck; Research grant/Funding (institution): PharmaMar. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.